Immungeniciteten af den nuværende køleskabs- stabile formulering viste sig at være den samme som immungeniciteten af den tidligere formulering af ProQuad seks uger efter en enkelt dosis af vaccinen.
Immunogenicity Immunogenicity was studied in children 12 through 23 months of age with a negative clinical history of measles, mumps, rubella, and varicella who participated in 5 randomized clinical trials. The immunogenicity of the current refrigerator-stable formulation was shown to be similar to the immunogenicity of the earlier formulation of ProQuad six weeks after a single dose of the vaccine.